Squarepoint
ARQT icon

Squarepoint’s Arcutis Biotherapeutics ARQT Stock Holding History

Squarepoint’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1M Sell
537,747
-565,743
-51% -$13.2M 0.02% 879
2026
Q1 		$26M Buy
1,103,490
+647,614
+142% +$16.5M 0.03% 573
2025
Q4 		$13.2M Buy
455,876
+296,029
+185% +$7.58M 0.01% 950
2025
Q3 		$3.01M Sell
159,847
-7,967
-5% -$126K ﹤0.01% 1778
2025
Q2 		$2.35M Buy
167,814
+105,487
+169% +$1.48M ﹤0.01% 1984
2025
Q1 		$975K Sell
62,327
-59,065
-49% -$832K ﹤0.01% 2688
2024
Q4 		$1.69M Buy
121,392
+48,769
+67% +$534K ﹤0.01% 2566
2024
Q3 		$675K Buy
+72,623
New +$717K ﹤0.01% 2898
2024
Q2 		– Sell
-205,870
Closed -$2.04M – 4031
2024
Q1 		$2.04M Buy
205,870
+56,447
+38% +$421K ﹤0.01% 2061
2023
Q4 		$483K Buy
149,423
+90,565
+154% +$246K ﹤0.01% 3027
2023
Q3 		$313K Buy
+58,858
New +$501K ﹤0.01% 3135
2023
Q1 		– Sell
-36,227
Closed -$536K – 3208
2022
Q4 		$536K Buy
36,227
+20,946
+137% +$366K ﹤0.01% 2239
2022
Q3 		$292K Buy
+15,281
New +$346K ﹤0.01% 2499
2021
Q2 		– Sell
-10,649
Closed -$308K – 3205
2021
Q1 		$308K Sell
10,649
-38,433
-78% -$1.2M ﹤0.01% 2372
2020
Q4 		$1.38M Buy
+49,082
New +$1.2M 0.01% 1142
2020
Q3 		– Sell
-12,422
Closed -$376K – 2475
2020
Q2 		$376K Buy
+12,422
New +$359K 0.01% 1468

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Squarepoint's ARQT Position: Q2 2026 in Review

Squarepoint reduced its Arcutis Biotherapeutics (ARQT) stake by 51% in Q2 2026, selling an estimated $13.2M and leaving 537,747 shares worth $14.1M. The position accounts for 0.02% of the portfolio, ranked #879.

Squarepoint first reported a position in ARQT in Q2 2020 and has held it in 16 quarters since. The position peaked at $26M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Squarepoint held 537,747 shares of Arcutis Biotherapeutics worth $14.1M as of Q2 2026.
  • Squarepoint sold 565,743 Arcutis Biotherapeutics shares in Q2 2026, an estimated $13.2M.
  • Arcutis Biotherapeutics made up 0.02% of Squarepoint's portfolio in Q2 2026, its #879 holding.
  • Squarepoint first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 16 quarters since.
  • Squarepoint's Arcutis Biotherapeutics position peaked at $26M in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.